TY - JOUR
T1 - Clinical features, treatment and outcome of pediatric patients with severe cutaneous manifestations in IgA vasculitis: multicenter international study
AU - Sestan, Mario
AU - Kifer, Nastasia
AU - Sozeri, Betul
AU - Demir, Ferhat
AU - Ulu, Kadir
AU - Silva, Clovis A.
AU - Campos, Reinan T.
AU - Batu, Ezgi Deniz
AU - Koker, Oya
AU - Sapina, Matej
AU - Srsen, Sasa
AU - Held, Martina
AU - Gagro, Alenka
AU - Fonseca, Adriana Rodrigues
AU - Rodrigues, Marta
AU - Rigante, Donato
AU - Filocamo, Giovanni
AU - Baldo, Francesco
AU - Heshin-Bekenstein, Merav
AU - Giani, Teresa
AU - Kataja, Janne
AU - Frkovic, Marijan
AU - Ruperto, Nicolino
AU - Ozen, Seza
AU - Jelusic, Marija
PY - 2023
Y1 - 2023
N2 - Objective: IgA vasculitis (IgAV) (formerly Henoch-Schonlein ¨ Purpura, HSP) rarely causes severe skin lesions in children. The purpose of the research was to determine whether severe skin manifestations were associated with a more severe disease course.
Methods: Severe cutaneous manifestations were defined as presence of hemorrhagic vesicles, bullae, ulcerations and/or necroses. Data were collected retrospectively from 12 international tertiary university medical centers.
Results: A total of 64 patients with the most severe skin changes in IgAV/HSP and median (Q1, Q3) age of 8.08 (5.08, 11.92) years at the disease onset were compared with 596 IgAV/HSP patients without these manfiestations and median (Q1, Q3) age of 6.33 (4.50, 8.92) years. The patients with severe cutaneous manifestations were older in comparison to other patients with IgAV/HSP (p<0.001), they developed nephritis more frequently (40.6% vs. 20.6%, p = 0.001) with worse outcome of renal disease (p = 0.001). This group of patients also had higher frequencies of severe gastrointestinal complications like hematochezia, massive bleeding and/or intussusception (29.3% vs. 14.8%, p<0.001). D-dimer concentrations were significantly higher in these patients (4.60 mg/L vs. 2.72 mg/L, p = 0.003) and they had more frequent need for treatment with systemic glucocorticoids (84.4% vs. 37.2%, p<0.001) in comparison with the control group. Further multivariate analysis showed that severe cutaneous changes were associated with higher risk of developing nephritis [OR=3.1 (95%CI 1.04–9.21), p = 0.042] and severe gastrointestinal complications [OR=3.65 (95%CI 1.08–12.37), p = 0.038].
Conclusion: Patients with IgAV/HSP and severe skin manifestations had a more severe clinical course and more frequently required glucocorticoids compared to classic IgAV/HSP patients.
AB - Objective: IgA vasculitis (IgAV) (formerly Henoch-Schonlein ¨ Purpura, HSP) rarely causes severe skin lesions in children. The purpose of the research was to determine whether severe skin manifestations were associated with a more severe disease course.
Methods: Severe cutaneous manifestations were defined as presence of hemorrhagic vesicles, bullae, ulcerations and/or necroses. Data were collected retrospectively from 12 international tertiary university medical centers.
Results: A total of 64 patients with the most severe skin changes in IgAV/HSP and median (Q1, Q3) age of 8.08 (5.08, 11.92) years at the disease onset were compared with 596 IgAV/HSP patients without these manfiestations and median (Q1, Q3) age of 6.33 (4.50, 8.92) years. The patients with severe cutaneous manifestations were older in comparison to other patients with IgAV/HSP (p<0.001), they developed nephritis more frequently (40.6% vs. 20.6%, p = 0.001) with worse outcome of renal disease (p = 0.001). This group of patients also had higher frequencies of severe gastrointestinal complications like hematochezia, massive bleeding and/or intussusception (29.3% vs. 14.8%, p<0.001). D-dimer concentrations were significantly higher in these patients (4.60 mg/L vs. 2.72 mg/L, p = 0.003) and they had more frequent need for treatment with systemic glucocorticoids (84.4% vs. 37.2%, p<0.001) in comparison with the control group. Further multivariate analysis showed that severe cutaneous changes were associated with higher risk of developing nephritis [OR=3.1 (95%CI 1.04–9.21), p = 0.042] and severe gastrointestinal complications [OR=3.65 (95%CI 1.08–12.37), p = 0.038].
Conclusion: Patients with IgAV/HSP and severe skin manifestations had a more severe clinical course and more frequently required glucocorticoids compared to classic IgAV/HSP patients.
KW - Henoch-Schonlein purpura
KW - Henoch-Schonlein purpura
UR - http://hdl.handle.net/10807/234590
U2 - 10.1016/j.semarthrit.2023.152209
DO - 10.1016/j.semarthrit.2023.152209
M3 - Article
SN - 0049-0172
VL - 61
SP - 1
EP - 7
JO - Seminars in Arthritis and Rheumatism
JF - Seminars in Arthritis and Rheumatism
ER -